This is a Cambridge University spin-out which in early May 2017 raised £7 million to discover new drugs to fight liver and lung disease caused by a major gene defect.
Z Factor was founded by the prolific Jim Huntington and again backed by David Grainger at Medicxi, among others.
The team is bidding to discover new drugs to treat Alpha-1-Antitrypsin Deficiency. AATD is a significant cause of liver and lung disease and results from a defect in the gene encoding Alpha-1-antitrypsin. Sufferers typically develop emphysema in their 30s.